Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks
NCT00418145
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Between the ages of 18 and 50 years, inclusive.
- Acute symptomatic exacerbation of MS present for great than 24 hours and less than or equal to 7 days at entry with new or worsening symptoms, and with signs referable to the symptoms; in the absence of a fever or active infection.
- Diagnosis of a relapsing form of multiple sclerosis before randomization as determined by Poser or McDonald Criteria.
- Expanded disability status scale (EDSS) score between 2 and 6.5, inclusive at entry.
- Episodes include study neurologist or neuro-ophthalmologist diagnosed: acute optic neuritis, cerebellar, brainstem dysfunction, myelitis, focal cerebral, and/or definitive focal sensory dysfunction.
- New objective clinical finding other than a sensory exacerbation, or bowel/bladder signs alone. Sensory deficits alone will not qualify except for optic neuritis.
- Subjects may continue on their current immunomodulating therapy (such as interferons or glatiramer acetate) throughout the course of the study. Women who become pregnant after the 5-day treatment of steroids should discontinue immunomodulatory treatment.
- Understand and sign written informed consent prior to any testing under this protocol, including screening tests and evaluations that are not considered part of the subject's routine care.
- Any patients treated with systemic corticosteroid use within one month of the index
episode at screening.
- Prior use of immunosuppressive treatments within 90 days of index episode
(mitoxantrone, azathioprine, IVIg) or plasmapheresis.
- Any patient who is pregnant or breastfeeding.
- Unable to perform the Multiple Sclerosis Functional Composite consisting of: Timed
25-Foot Walk, 9-Hole Peg Test, and Paced Auditory Serial Addition Test (3 second).
- Peripheral or cranial neuropathy as sole problem of acute episode.
- History of any significant cardiac, gastrointestinal, hepatic, pulmonary, or renal
disease; immune deficiency; or other medical conditions that would preclude
corticosteroid therapy.
- Primary Progressive Multiple Sclerosis (PPMS).
- Previous participation in this study.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- New Brunswick, New Jersey
- Brooklyn, New York
- Buffalo, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- Rochester, New York
- Burlington, Vermont
- Columbus, Ohio
- Rockland, Massachusetts
- Rockland, Massachusetts
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks | |||
Official Title ICMJE | Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA) | |||
Brief Summary | This clinical trial compares the relative efficacy of treating acute exacerbations of relapsing forms of Multiple Sclerosis with equivalent doses of oral and intravenous (IV) methylprednisolone. This is a randomized, blinded, multi-center study. | |||
Detailed Description | Intravenous methylprednisolone has been the standard of care for treating acute MS flares. However, the IV administration is cumbersome, inconvenient and expensive. A true comparison of these different approaches has not been undertaken in rigorous fashion. Prior studies have demonstrated the safety of such high doses of oral steroid. For this proposal we employ equivalent oral dosing (1400 mg/day) and compare that to 1000 mg/day IV therapy in patients seen within seven days of an acute exacerbation of MS. In addition, there are 2 arms to this double-blind, placebo controlled, randomized trial. One arm has an active IV and an oral placebo while the second arm has an IV placebo and an active oral dose. Therefore, each subject will receive an active treatment. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
Condition ICMJE | Multiple Sclerosis | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Terminated | |||
Actual Enrollment ICMJE | 16 | |||
Original Enrollment ICMJE | 120 | |||
Actual Study Completion Date ICMJE | October 2013 | |||
Actual Primary Completion Date | October 2013 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 50 Years (Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00418145 | |||
Other Study ID Numbers ICMJE | GCO 01-0781 RG 3363A8 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Fred Lublin, Icahn School of Medicine at Mount Sinai | |||
Study Sponsor ICMJE | Fred Lublin | |||
Collaborators ICMJE |
| |||
Investigators ICMJE |
| |||
PRS Account | Icahn School of Medicine at Mount Sinai | |||
Verification Date | April 2017 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |